Over the past twenty years I have been repeatedly surprised that such a high proportion of cancer research workers have chosen to work on the induction and growth rate of cancer and so few on the spread of the disease.
Modern surgery, combined with other therapy, would be capable of curing the majority of cancer cases if the tumour could be contained within a discrete region as a primary noninvasive cancer. Surgery may therefore be helped either by the earlier diagnosis of the primary tumour or else by limiting its spread. These two aspects are important to the effective control of the disease.
The main reason for the apparent neglect of cancer dissemination lies in the fact that animal models of the human condition have proved unsatisfactory. A major problem is the development of specific test systems in animals which bear a sufficiently close relationship to human tumours. It is only comparatively recently that our understanding of the in vitro culture of both human and animal tissues has developed sufficiently to give confidence that one is dealing with growing, rather than dying tissues. Some form of direct comparison between experimental and spontaneous human tumours would provide a much needed bridge between the experimental scientist and the clinician. It may even be possible to relate the vast quantity of information on experimental tumours which is already available to human cancer. Secondary metastatic tumours often have properties quite different from those of the primary from which they were derived and information on this relationship would also be most useful in determining the correct treatment for a specific tumour.
Although I cannot hope to review the work which has already been carried out on these various aspects I should like to discuss some of the factors which require further study using some of our current work in illustration.
Control ofthe Primary Tumour
It is a matter of clinical observation that tumours differ in ease of metastasis. It does not appear to be a matter of size of primary tumour, and morphology or biochemistry can only give an estimate of this tendency. It is perhaps convenient to think of some type of 'ripening process' of the tumour which renders it ready to spread. Is it possible to control this process through hormonal intervention or perhaps enzyme inhibition?
A good example of a drug which prevents the tumour metastasis at this early stage is ICRF 159 which has been developed by Dr K Hellmann and his colleagues. This drug prevents metastasis by a process which is apparently linked with changes in the vascular system of the tumour which in turn prevents the release of metastatic cells (Hellmann 1972) .
Breakdown ofthe Primary Tumour
The question as to what causes the tumour to become metastatic is obviously very important. Our own experience and that of others suggests that an enzyme system, probably a proteolytic enzyme, plays a part in this breakdown and it would be most valuable if an inhibitor could be found.
Some years ago, Dr D M Robertson showed that there is an enhanced collagenase activity at the surface of an invading tumour and that the collagenase levels appeared to bear some relationship to the 'ripening' process of the tumour. Many of the 'model' experiments which are based upon the injection of homogenized tumour cells are not valid as the cells are in fact not sufficiently similar to those released from a mature tumour (Robertson & Williams 1969) .
A most interesting piece of work has recently been carried out by Dr J J M Rowe who has been investigating the activity of a range of catheptic enzymes in both tumour and host. These enzymes have been purified by iso-electric techniques. It was shown that a synergic effect could be produced when a small amount of enzyme from a tumour was added to a larger amount of enzyme from normal tissues. This suggests that, at the tumour host boundary, the proteolytic activity is enhanced by the interaction between the tumour and host enzymes causing an area of high proteolytic activity with consequent increased spread of the tumour. It remains to be seen whether this localized activity can be modified by chemical inhibitors, immunological intervention or other means.
There is considerable evidence that certain tumours metastasize as clumps of cells and that individual cells are not themselves viable. It would be most valuable if the optimum size of cell clump for metastasis could be determined, as it seems possible that increasing the levels of proteolytic enzyme in blood may degrade these clumps to less than viable size.
Thus we may have opposing functions for these enzyme systems in the metastatic process. A high local activity at the tumour host interface would increase the number of free clumps of malignant cells, but a high blood or lymph proteolytic activity may degrade these clumps to less than viable size and so prevent secondary growth.
Transport ofCells in Body Fluids
The metastatic cell would seem most vulnerable to attack by alkylating agents or antimetabolic compounds at the time when it is 'in transit' between its primary tumour and secondary site.
Many attempts have been made to influence the course of metastatic spread by chemotherapy but these treatments have proved largely unsuccessful.
There is considerable clinical evidence that a tumour can be proliferated by mechanical stress, such as that experienced during surgery, so that an agent to protect the patient for even this relatively short period would be very useful. It must be remembered, however, that the action of most cytotoxic drugs depends on the penetration of the drug into the dividing cell and this appears to take place at a specific point in the cell cycle. It seems likely that the time for transport of the cells is not long enough to allow the cytotoxic drugs to exert a major effect and also that cell division is restricted to what is rather akin to a tissue culture system. This aspect of the problem would seem worthy of further examination by carefully con-trolled tissue culture experiments. Another possibility is the artificial stimulation of the growth rate of metastasizing cells so that, on average, the sensitive phase of a given cell is reached more often but there is a danger that this treatment may actually increase the rate of metastasis.
Selection ofSecondary Site by Specific Tunours
It has long been recognized that a particular tumour will tend to metastasize to a well defined secondary site. In some cases this tendency is explicable by the simple filtration of colonies of cells by vascular organs or lymph glands. In other cases, however, a more specific mechanism must be involved.
Some years ago we set out to investigate the factors involved in the predilection for breast cancer to metastasize to bone (Robertson & Williams 1964 ). Our model system was a simple one consisting of crushed bone chips in a tissue culture medium to which tumour extracts and test substances could be added. When rat mammary tumour slices were incubated in this system a considerable release of calcium into the medium was observed. This effect could be increased by cortisone and vitamin D derivatives. A similar effect was obtained from serum extract from both tumour bearing animals and cancer patients. Attempts to isolate the active principle from serum by electrophoresis and other means yielded a number of different fraction having similar activity which appeared to be low molecular weight polypeptides. It may be that work on the development of inhibitors of these substances would lead to a means of controlling bone erosion and possibly control the metastasis of tumours to bone.
Implantation ofSecondary Tumour
The moment at which the malignant cell attaches itself to the host tissue is a key point in the whole process of metastasis at which immune rejection of the cell may be expected, but is not effective. There remains the possibility of improving the effects of cytostatic drugs with non-specific stimulators of the immune system. A good example of this is the elegant work of Currie & Bagshawe (1969) who showed that the cytotoxic effect of alkylating agents against mouse leukemia could be potentiated by Corynebacterium parvum extracts. We have also found a definite sex difference in response to this treatment. This effect may, therefore, be still further improved by combining hormone manipulation with this treatment. Preliminary experiments to test this are now being undertaken.
We are, I believe, just beginning to understand some of the cell surface properties which are involved during implantation. Dr P Whur in our laboratory has produced some scanning electron micrographs of mouse tumour cells in the process of implantation which suggests that this process is, to some extent, enzyme initiated and that trypsin and its inhibitors appear to be involved.
Growth ofthe Secondary Tumours
The mechanism whereby a secondary tumour is able to erode away the host tissue and replace it by malignant tissues has been widely studied, but the application of such knowledge to the control of the invasive processes is still in its infancy. The tumour cells in the invasion zone are powerful secretors of lysosomal enzymes all of which have specific roles in the destruction of whole cells and their components. These enzymes are released into the boundary zone between tumour and host tissue and are responsible for the destruction of the host tissue matrix initially and the surrounding host cells finally, allowing tumour cells to infiltrate into the invasion zone and the process is continuously repeated.
The extracellular fluid of the tumour/host boundary has been investigated by many workers and it is now clear that lysosomal acid hydrolases, such as the cathepsins, acid phosphatases and fl-glucuronidase, are present in concentrations of one or two magnitudes higher than those found in normal tissue.
The conditions ofhigh concentrations of hydrolytic enzymes operating in a comparatively low pH environment are probably unique for tumour tissue, so that inhibition of the hydrolytic enzymes secreted by the tumour tissue should have a pronounced affect on the invasiveness of the tumour.
There is need therefore for a specific inhibitor of these enzymes but so far experiments with chemical enzyme inhibitors have been disappointing owing to the lack of specificity.
Mr R G Harris in out laboratories has been trying to develop a specific method of immunization against these enzymes in the hope that it may be used against metastasis either alone or in combination with chemical inhibitors. His results, thus far, suggest that there is a degree of tumour specificity between the antisera of normal and malignant tissues in vitro. Experiments are now being carried out to see if this absorbed antiserum exerts the same effect under in vivo conditions. Hormone Sensitive Tumours Hormone sensitive secondary tumours have been treated with varying success by hormonal manipulation either surgical or chemical. The two major problems in this form of therapy seem to be that it is very difficult to remove all sources of particular hormone and that secondary growths may not have the same hormonal response as the primary tumour from which they arise and in any case such tumours may quickly become autonomous.
In the case of hormone sensitive tumours there is a further possibility involving immunological methods. This arises from the classical work of Lieberman and his group who have shown that it is possible to immunize against steroid hormones and by this means inactivate the biological effects of these substances. In particular, it has been clearly shown that both exogenous and endogenous oestrogens can be biologically inactivated by antibodies to cestradiol-17fl. Antibodies to oestradiol did not counteract androgenic effects upon accessory sex organs produced by testosterone, nor did antibodies elicited by testosterone alter the effects of cestradiol-17,B. In contrast to anti-aestrogens which act at the target organs, the specific antibodies probably neutralize endogenous hormone in the peripheral blood and thus provide a means of controlling endogenous hormone outside of the target organ (Ferin et al. 1968 ).
The implication of this work to steroid sensitive tumour needs no underlining and techniques based on these experiments are being developed in several laboratories including our own.
An experiment which may throw some light on the second of these problems was performed recently by Dr N P Bishun. He cloned a rat mammary tumour using cytogenetic parameters and found that both in vitro and in vivo some clones would not grow in the absence of others, but that by remixing the clones growth could then be mutually restored. Could this not explain the observed clinical fact that, very occasionally, the removal of the primary tumour causes regression of secondary growths? Is this an example of ectopic hormone? Conclusion I realize of course that many of the points which I have mentioned are open to criticismit may well be that we disagree on most. I am sure, however, that we shall all agree that a detailed examination of the individual factors which comprise tumour dissemination is worthy of a great deal of attention in the future.
